Literature DB >> 8024653

Skewed T-cell receptor usage and junctional heterogeneity among isletitis alpha beta and gamma delta T-cells in human IDDM [corrected].

P Santamaria1, C Lewis, J Jessurun, D E Sutherland, J J Barbosa.   

Abstract

Because of anatomical limitations, molecular characterization of islet-inflammatory T-cells in human insulin-dependent diabetes mellitus (IDDM) has remained elusive. We have isolated isletitis T-cells from pancreas graft biopsies of two patients (syngeneic and allogeneic, respectively) shortly after onset of recurrent IDDM and have characterized their repertoire by sequencing T-cell receptor (TcR)-specific cDNAs. Histopathological analysis of the grafts revealed selective beta-cell loss and isletitis characteristic of recurrent disease with no evidence of chronic inflammation or rejection. Most of the in vivo-activated isletitis T-cells were CD8+TcR alpha beta+ and CD4-CD8-TcR gamma delta+ in both patients. Comparison of the different TcR alpha,beta,gamma, and delta sequences revealed V(D)J junctional heterogeneity but skewed TcR usage within patients. Eighth of 13 different isletitis TcR beta sequences (19 of 26 cDNAs) from the syngeneic graft of patient 1 were V beta 3+, as opposed to only 1 of 31 peripheral TcR beta sequences (1 of 31 cDNAs) (61.5 vs. 3.2%, P < 0.0001). Of the 19 different isletitis TcR alpha clonotypes of this patient (24 of 42 cDNAs), 5 were V alpha 14+. The isletitis TcR beta clonotypes of the human leukocyte antigen-identical allogeneic graft of patient 2 showed selective J beta, but not V beta, gene usage. Two of three predominant isletitis clonotypes of patient 2 were V alpha 22+ (19 of 28 cDNAs) and the other (5 of 28 cDNAs) was also V alpha 14+.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024653     DOI: 10.2337/diab.43.4.599

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

Review 1.  T cell receptor usage in autoimmune disease.

Authors:  P Moss; J Bell
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.

Authors:  Zoltan Antal; Jason C Baker; Carla Smith; Irene Jarchum; Jeffrey Babad; Gayatri Mukherjee; Yang Yang; John Sidney; Alessandro Sette; Pere Santamaria; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

3.  γδ T cells are essential effectors of type 1 diabetes in the nonobese diabetic mouse model.

Authors:  Janet G M Markle; Steve Mortin-Toth; Andrea S L Wong; Liping Geng; Adrian Hayday; Jayne S Danska
Journal:  J Immunol       Date:  2013-04-26       Impact factor: 5.422

4.  Double negative (CD3+ 4- 8-) TCR alphabeta splenic cells from young NOD mice provide long-lasting protection against type 1 diabetes.

Authors:  Beverly Duncan; Cristina Nazarov-Stoica; Jacqueline Surls; Margaret Kehl; Constantin Bona; Sofia Casares; Teodor-D Brumeanu
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

5.  Identification of novel IGRP epitopes targeted in type 1 diabetes patients.

Authors:  Irene Jarchum; Lynn Nichol; Massimo Trucco; Pere Santamaria; Teresa P DiLorenzo
Journal:  Clin Immunol       Date:  2008-03-20       Impact factor: 3.969

6.  Efficient culture of CD8(+) T cells from the islets of NOD mice and their use for the study of autoreactive specificities.

Authors:  Irene Jarchum; Toshiyuki Takaki; Teresa P DiLorenzo
Journal:  J Immunol Methods       Date:  2008-09-07       Impact factor: 2.303

7.  Predominant occupation of the class I MHC molecule H-2Kwm7 with a single self-peptide suggests a mechanism for its diabetes-protective effect.

Authors:  Daniel R Brims; Jie Qian; Irene Jarchum; Leann Mikesh; Edith Palmieri; Udupi A Ramagopal; Vladimir N Malashkevich; Rodolfo J Chaparro; Torben Lund; Masakazu Hattori; Jeffrey Shabanowitz; Donald F Hunt; Stanley G Nathenson; Steven C Almo; Teresa P Dilorenzo
Journal:  Int Immunol       Date:  2010-01-21       Impact factor: 4.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.